top of page
Search

Psychedelics and Trauma: An Emerging Path to Healing

The exploration of psychedelics as potential therapeutic agents for mental health conditions has surged over the past few years. This renewed interest reflects the recognition of their potential healing capabilities, especially in treating traumatic experiences. This blog post will discuss the emerging research on the use of psychedelics for trauma healing, focusing on substances like MDMA, psilocybin, and LSD.

The Potential of Psychedelics for Trauma Healing

Psychedelics, such as MDMA (3,4-Methylenedioxymethamphetamine), psilocybin (the active compound in "magic mushrooms"), and LSD (Lysergic Acid Diethylamide), have shown promising results in treating mental health conditions, including those rooted in trauma (Nichols, 2016).

MDMA-Assisted Psychotherapy for PTSD

MDMA, commonly known as "Ecstasy" or "Molly," is a psychoactive drug that induces feelings of euphoria, increased energy, and emotional warmth. These characteristics make it a potentially valuable tool in psychotherapy, particularly for individuals with post-traumatic stress disorder (PTSD).

Multiple studies have shown that MDMA-assisted psychotherapy can help reduce symptoms of PTSD (Mithoefer et al., 2018). Unlike traditional pharmaceutical treatments, MDMA does not just suppress symptoms but may facilitate the therapeutic process by increasing feelings of trust and empathy and decreasing feelings of fear and defensiveness.

Psilocybin Therapy for Psychological Distress

Psilocybin, the active compound in psychedelic mushrooms, has been found to be effective in reducing symptoms of depression, anxiety, and psychological distress, often associated with trauma (Carhart-Harris et al., 2016). Researchers propose that psilocybin's ability to induce profound, meaningful spiritual experiences and its impact on the brain's neuroplasticity contribute to its therapeutic effects.

LSD and Trauma Treatment

LSD, a potent psychedelic, has a long history of research and usage in psychotherapy. Recent studies have begun to re-explore its therapeutic potential. One study found that LSD-assisted psychotherapy resulted in a reduction in anxiety experienced by individuals with life-threatening diseases (Gasser et al., 2014).

The Neuroscience of Psychedelics

Psychedelics exert their effects primarily through the serotonin 2A receptor in the brain (Carhart-Harris et al., 2012). This interaction can induce a range of effects, from visual and perceptual changes to more profound, subjective experiences of self-transcendence and unity.

Emerging neuroimaging research suggests that psychedelics can increase connectivity in the brain, potentially helping to foster new perspectives and cognitive flexibility (Carhart-Harris et al., 2014). This neuroplastic effect of psychedelics could be beneficial for those suffering from trauma, whose brains may be "stuck" in harmful thought patterns or behaviors.

Safety and Ethical Considerations

While the therapeutic potential of psychedelics is promising, it's essential to remember that these substances should be used under the supervision of trained professionals. Unsupervised use of psychedelics can lead to harmful experiences, especially for individuals with a history of psychosis or other serious mental health conditions (Johnson et al., 2008).

Conclusion

While research into the therapeutic application of psychedelics for trauma is still in its infancy, early results are promising. These substances have the potential to provide new avenues for healing for individuals suffering from the impacts of traumatic experiences. However, further research is needed to fully understand their therapeutic potential and safety profile.



Psychedelics and Trauma

Reach out today for a free consultation with a therapist in Boulder, CO.


References:


  1. Nichols, D. E. (2016). Psychedelics. Pharmacological Reviews, 68(2), 264-355.

  2. Mithoefer, M. C., Mithoefer, A. T., Feduccia, A. A., Jerome, L., Wagner, M., Wymer, J., Holland, J., Hamilton, S., Yazar-Klosinski, B., Emerson, A., & Doblin, R. (2018). 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for post-traumatic stress disorder in military veterans, firefighters, and police officers: a randomised, double-blind, dose-response, phase 2 clinical trial. The Lancet Psychiatry, 5(6), 486-497.

  3. Carhart-Harris, R. L., Bolstridge, M., Rucker, J., Day, C. M., Erritzoe, D., Kaelen, M., Bloomfield, M., Rickard, J. A., Forbes, B., Feilding, A., Taylor, D., Pilling, S., Curran, V. H., & Nutt, D. J. (2016). Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. The Lancet Psychiatry, 3(7), 619-627.

  4. Gasser, P., Holstein, D., Michel, Y., Doblin, R., Yazar-Klosinski, B., Passie, T., & Brenneisen, R. (2014). Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases. The Journal of Nervous and Mental Disease, 202(7), 513.

  5. Carhart-Harris, R. L., Erritzoe, D., Williams, T., Stone, J. M., Reed, L. J., Colasanti, A., Tyacke, R. J., Leech, R., Malizia, A. L., Murphy, K., Hobden, P., Evans, J., Feilding, A., Wise, R. G., & Nutt, D. J. (2012). Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin. Proceedings of the National Academy of Sciences, 109(6), 2138-2143.

  6. Carhart-Harris, R. L., Leech, R., Hellyer, P. J., Shanahan, M., Feilding, A., Tagliazucchi, E., Chialvo, D. R., & Nutt, D. (2014). The entropic brain: a theory of conscious states informed by neuroimaging research with psychedelic drugs. Frontiers in Human Neuroscience, 8, 20.

  7. Johnson, M. W., Richards, W. A., & Griffiths, R. R. (2008). Human hallucinogen research: guidelines for safety. Journal of Psychopharmacology, 22(6), 603-620.



10 views0 comments

Comments


bottom of page